All Updates

All Updates

icon
Filter
Funding
Praxis Precision Medicines announces USD 59.1 million underwritten public offering
Precision Medicine
Jun 15, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Jun 15, 2023

Praxis Precision Medicines announces USD 59.1 million underwritten public offering

Funding

  • Drug developer Praxis Precision Medicines announced an underwritten public offering of its common shares and pre-funded warrants. The offering includes 55.2 million common shares and pre-funded warrants to purchase up to 7.1 common shares. With a price set at USD 0.95 per share, the company aims to raise approximately USD 59.1 million.

  • Additionally, the company has also granted the underwriters a 30-day option to purchase an additional 9.3 million shares at the same price. The offering is expected to close on June 21, 2023, and the use of net proceeds was not disclosed.

  • The capital raised from this offering will likely support Praxis Precision Medicines' ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.

  • The public offering is being facilitated by Piper Sandler and Truist Securities, who are serving as the joint book-running managers for the offering. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.